Full Proxy Statement Filed for Yarrow Bioscience Reverse Merger, Detailing Shareholder Vote on Dilution, Cash Dividend, and Reverse Split

summarizeSummary

VYNE Therapeutics filed the full proxy statement for its reverse merger with Yarrow Bioscience, detailing the significant dilution for existing shareholders, a cash dividend, and a large capital raise for the combined entity, all subject to shareholder approval.

check_boxKey Events

• Reverse Merger Details Confirmed

  VYNE Therapeutics is proceeding with a reverse merger with Yarrow Bioscience, Inc., with VYNE to be renamed 'Yarrow Bioscience, Inc.' and trade under the symbol 'YARW' on Nasdaq.

• Significant Shareholder Dilution

  Existing VYNE securityholders are expected to own approximately 3.0% of the outstanding shares of the Combined Company on a fully-diluted basis post-merger.

• Substantial Capital Raise for Yarrow

  The transaction includes a $200 million aggregate pre-closing financing for Yarrow, comprising a $100 million private placement already closed and an additional $100 million pre-closing financing.

• Special Cash Dividend for VYNE Shareholders

  Prior to the merger, VYNE expects to declare a special cash dividend of approximately $14.5 million to $16.5 million to its existing shareholders.

auto_awesomeAnalysis

This S-4 filing provides the comprehensive proxy statement and prospectus for the proposed reverse merger with Yarrow Bioscience. It details the significant dilution for existing VYNE shareholders, who are expected to own only 3.0% of the combined company, alongside a substantial $200 million pre-closing financing for Yarrow. The filing also outlines a special cash dividend of $14.5 million to $16.5 million for current VYNE shareholders and the necessity of a reverse stock split (1-for-10 to 1-for-70) to maintain Nasdaq listing. This document is critical for shareholders to make informed decisions on the transformative transaction, which represents a strategic pivot for VYNE from its struggling legacy business.